Moroctocog alfa

Moroctocog alfa is a glycoprotein (trade name ReFacto) and an recombinant Antihemophilic Factor genetically engineered from Chinese hamster ovary (CHO) cell line^[1]. It is manufactured by Genetics Institute, Inc. and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients with hemophilia A. It is partially a recombinant coagulation factor VIII since it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII)^[2]. It also has posttranslational modifications which are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated with von Willebrand's disease since it's not a von Willebrand factor.

Reference

1. ^ http://www.abopharmaceuticals.com/ProductSheets/Refacto.pdf
2. ^ http://www.ema.europa.eu/humandocs/PDFs/EPAR/Refacto/058999en6.pdf

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.v · Categories: Recombinant proteins Blood and blood forming organ drug stubs Wikimedia Foundation. 2010. Игры ⚽ Поможем решить контрольную работу Morococha Morodo 18+ © Academic, 2000-2024 Contact us: Technical Support, Advertising Dictionaries export, created on PHP, Joomla, Drupal, WordPress, MODx. Mark and share Search through all dictionaries Translate… Search Internet Share the article and excerpts Direct link … Do a right-click on the link above and select “Copy Link”